Global Human Coagulation Factor VIII Market Growth 2025-2031

The global Human Coagulation Factor VIII market size is predicted to grow from US$ 11940 million in 2025 to US$ 17450 million in 2031; it is expected to grow at a CAGR of 6.5% from 2025 to 2031.

Human Coagulation Factor VIII is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). In humans, factor VIII is encoded by the F8 gene, defects in this gene results in hemophilia A. Human Coagulation Factor VIII concentrated from donated blood plasma (Aafact or Alphanate, Monoclate-P®), or alternatively recombinant Human Coagulation Factor VIII can be given to hemophiliacs to restore hemostasis.

Market Drivers:

The increasing prevalence of hemophilia A is a key driver for the Human Coagulation Factor VIII market. As awareness and diagnosis rates improve, more patients are receiving proper treatment, driving demand for Factor VIII therapies. Additionally, advancements in biotechnology, including the development of recombinant and extended half-life Factor VIII products, have significantly improved treatment efficacy and patient convenience. Government initiatives and healthcare programs supporting rare disease treatments, along with expanded access to hemophilia care in developing regions, further boost market growth. The rise of gene therapy research also presents potential future opportunities for transforming the hemophilia treatment landscape.

Market Challenges:

Despite strong market growth, several challenges persist, including the high cost of Factor VIII therapies, which limits affordability and accessibility for many patients, especially in low-income regions. Additionally, plasma-derived Factor VIII products face supply chain constraints due to reliance on blood donations. Another major challenge is the development of inhibitors (antibodies) in some patients, which can render Factor VIII treatment ineffective and necessitate alternative therapies. Regulatory complexities and the need for stringent quality control in manufacturing also pose barriers for new entrants in the market.

LP Information, Inc. (LPI) ' newest research report, the “Human Coagulation Factor VIII Industry Forecast” looks at past sales and reviews total world Human Coagulation Factor VIII sales in 2024, providing a comprehensive analysis by region and market sector of projected Human Coagulation Factor VIII sales for 2025 through 2031. With Human Coagulation Factor VIII sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Human Coagulation Factor VIII industry.

This Insight Report provides a comprehensive analysis of the global Human Coagulation Factor VIII landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Human Coagulation Factor VIII portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Human Coagulation Factor VIII market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Human Coagulation Factor VIII and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Human Coagulation Factor VIII.

This report presents a comprehensive overview, market shares, and growth opportunities of Human Coagulation Factor VIII market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Recombinant Factor VIII
Plasma-derived Factor VIII

Segmentation by Application:
Hemophilia A
Spontanous / Trauma
Surgical
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Takeda
Bayer
CSL
Pfizer
Grifols
Biogen
Octapharma
NovoNordisk
Greencross
Kedrion
BPL
Hualan Bio
RAAS
SinoCellTech
Taibang Bio
Huarun Boya
Shuanglin Bio
Yuandashuyang
Weiguang Bio

Key Questions Addressed in this Report

What is the 10-year outlook for the global Human Coagulation Factor VIII market?

What factors are driving Human Coagulation Factor VIII market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Human Coagulation Factor VIII market opportunities vary by end market size?

How does Human Coagulation Factor VIII break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.